<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004833</url>
  </required_header>
  <id_info>
    <org_study_id>199/13444</org_study_id>
    <secondary_id>EUSM-076-97</secondary_id>
    <secondary_id>EUSM-FDR001265</secondary_id>
    <nct_id>NCT00004833</nct_id>
  </id_info>
  <brief_title>Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the efficacy of plasmapheresis and human immunoglobulin infusion in minimizing&#xD;
      morbidity and augmenting the pace of recovery in children with Guillain-Barre syndrome.&#xD;
&#xD;
      II. Compare the potential risks, in terms of treatment related side effects and adverse&#xD;
      clinical outcome, between these two treatment modalities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a randomized, multicenter study.&#xD;
&#xD;
      Patients are randomized to receive either human immunoglobulin infusion (IVIg) (arm I) or&#xD;
      plasmapheresis (arm II).&#xD;
&#xD;
      Arm I patients receive liquid heat-treated IVIg for 4 days starting on day 1 and then another&#xD;
      single infusion of IVIg on day 7, 8, or 9.&#xD;
&#xD;
      Arm II patients receive serial plasmapheresis treatments. The first exchange is given on day&#xD;
      1 and the remaining exchanges are given over the next 5-10 days.&#xD;
&#xD;
      Patients are followed at weeks 1, 2, 3, 4, 8, 12, and 24.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 1995</start_date>
  <completion_date>November 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>170</enrollment>
  <condition>Guillain-Barre Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune globulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Guillain-Barre syndrome (GBS): Progressive weakness of two or more limbs; Absence or&#xD;
        reduced tendon reflexes; No atypical symptoms of GBS (e.g., Miller-Fisher variant); No pure&#xD;
        sensory neuropathy; No prior history of GBS&#xD;
&#xD;
        Disability at least grade 3 according to Guillain-Barre Study Group grading scale (unable&#xD;
        to walk 5 meters without assistance); Must not have improvement of one or more disability&#xD;
        grades prior to randomization in this study&#xD;
&#xD;
        No paresthesias, numbness, or weakness that began more than 14 days before randomization in&#xD;
        this study&#xD;
&#xD;
        No CNS involvement&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Biologic therapy: No prior treatment with plasmapheresis or infusion of human&#xD;
        immunoglobulin (IVIg)&#xD;
&#xD;
        Endocrine therapy: No concurrent corticosteroids or other immunosuppressants (except for&#xD;
        concurrent medical conditions, e.g., asthma)&#xD;
&#xD;
        Radiotherapy: Not specified&#xD;
&#xD;
        Surgery: Not specified&#xD;
&#xD;
        Other: No concurrent mechanical ventilation&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Age: Under 18 but with at least 3 months of independent walking&#xD;
&#xD;
        Hematopoietic: Cerebrospinal fluid leukocyte count less than 50/mm3&#xD;
&#xD;
        Hepatic: No liver failure&#xD;
&#xD;
        Renal: No kidney failure&#xD;
&#xD;
        Neurological: No other major neurologic diseases, other neuromuscular disorders, or&#xD;
        cerebral palsy&#xD;
&#xD;
        Other: HIV negative; No contraindications to plasmapheresis or IVIg; No severe uncontrolled&#xD;
        infection; No known IgA hypersensitivity; No other preexisting disease that would interfere&#xD;
        with assessment of disability grades; No other causes of acquired weakness (e.g.,&#xD;
        poliomyelitis, botulism, or other etiologies); No diabetes; Not pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John T. Sladky</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <verification_date>September 2002</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <keyword>Guillain-Barre syndrome</keyword>
  <keyword>demyelinating neuropathy</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

